|
1
|
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.
|
Clin Cancer Res
|
2004
|
16.51
|
|
2
|
HER-2 testing in breast cancer using parallel tissue-based methods.
|
JAMA
|
2004
|
4.60
|
|
3
|
Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival.
|
J Clin Oncol
|
2006
|
3.42
|
|
4
|
CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas.
|
Am J Surg Pathol
|
2003
|
3.39
|
|
5
|
An international Ki67 reproducibility study.
|
J Natl Cancer Inst
|
2013
|
2.46
|
|
6
|
Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers.
|
J Clin Oncol
|
2008
|
2.38
|
|
7
|
Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories.
|
J Clin Oncol
|
2010
|
2.28
|
|
8
|
Implementation of a Canadian external quality assurance program for breast cancer biomarkers: an initiative of Canadian Quality Control in immunohistochemistry (cIQc) and Canadian Association of Pathologists (CAP) National Standards Committee/Immunohistochemistry.
|
Appl Immunohistochem Mol Morphol
|
2009
|
2.22
|
|
9
|
Pure epithelioid PEComas (so-called epithelioid angiomyolipoma) of the kidney: A clinicopathologic study of 41 cases: detailed assessment of morphology and risk stratification.
|
Am J Surg Pathol
|
2011
|
1.99
|
|
10
|
Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group.
|
Arch Pathol Lab Med
|
2009
|
1.85
|
|
11
|
Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases.
|
Breast Cancer Res Treat
|
2007
|
1.75
|
|
12
|
Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism.
|
Cancer Res
|
2008
|
1.73
|
|
13
|
Thyroid transcription factor-1 expression in breast carcinomas.
|
Am J Surg Pathol
|
2010
|
1.65
|
|
14
|
Nuclear beta-catenin in mesenchymal tumors.
|
Mod Pathol
|
2005
|
1.60
|
|
15
|
Cytokeratins 7 and 20 in primary and secondary mucinous tumors of the ovary: analysis of coordinate immunohistochemical expression profiles and staining distribution in 179 cases.
|
Am J Surg Pathol
|
2006
|
1.44
|
|
16
|
Unmasking the mysteries of antigen or epitope retrieval and formalin fixation.
|
Am J Clin Pathol
|
2004
|
1.39
|
|
17
|
Intracystic papillary carcinomas of the breast: a reevaluation using a panel of myoepithelial cell markers.
|
Am J Surg Pathol
|
2006
|
1.36
|
|
18
|
Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7.
|
Mod Pathol
|
2006
|
1.34
|
|
19
|
Perlecan protein core interacts with extracellular matrix protein 1 (ECM1), a glycoprotein involved in bone formation and angiogenesis.
|
J Biol Chem
|
2003
|
1.31
|
|
20
|
Ovarian mucinous tumors associated with mature cystic teratomas: morphologic and immunohistochemical analysis identifies a subset of potential teratomatous origin that shares features of lower gastrointestinal tract mucinous tumors more commonly encountered as secondary tumors in the ovary.
|
Am J Surg Pathol
|
2007
|
1.23
|
|
21
|
Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples.
|
Am J Surg Pathol
|
2010
|
1.22
|
|
22
|
Carcinoma of the collecting ducts of Bellini and renal medullary carcinoma: clinicopathologic analysis of 52 cases of rare aggressive subtypes of renal cell carcinoma with a focus on their interrelationship.
|
Am J Surg Pathol
|
2012
|
1.21
|
|
23
|
Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity.
|
Mod Pathol
|
2006
|
1.20
|
|
24
|
Best practices in diagnostic immunohistochemistry: hepatocellular carcinoma versus metastatic neoplasms.
|
Arch Pathol Lab Med
|
2007
|
1.19
|
|
25
|
Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain.
|
Am J Surg Pathol
|
2003
|
1.16
|
|
26
|
Diagnostic utility of galectin-3 in thyroid cancer.
|
Am J Pathol
|
2010
|
1.14
|
|
27
|
Pharmacologically regulated in vivo selection in a large animal.
|
Blood
|
2002
|
1.12
|
|
28
|
Fluorescence in situ hybridization for the detection of t(X;18)(p11.2;q11.2) in a synovial sarcoma tissue microarray using a breakapart-style probe.
|
Diagn Mol Pathol
|
2005
|
1.09
|
|
29
|
Vaginal lymphatic channel location and its implication for intracavitary brachytherapy radiation treatment.
|
Brachytherapy
|
2005
|
1.08
|
|
30
|
Aberrant expression of epithelial and neuroendocrine markers in alveolar rhabdomyosarcoma: a potentially serious diagnostic pitfall.
|
Mod Pathol
|
2008
|
1.05
|
|
31
|
Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy.
|
J Clin Oncol
|
2011
|
1.05
|
|
32
|
p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas.
|
Am J Surg Pathol
|
2007
|
1.02
|
|
33
|
Immunohistochemistry for estrogen and progesterone receptors in the distinction of primary and metastatic mucinous tumors in the ovary: an analysis of 124 cases.
|
Mod Pathol
|
2006
|
1.01
|
|
34
|
Nonsmall cell lung carcinoma with neuroendocrine differentiation--an entity of no clinical or prognostic significance.
|
Am J Surg Pathol
|
2007
|
1.00
|
|
35
|
Best practices in diagnostic immunohistochemistry: myoepithelial markers in breast pathology.
|
Arch Pathol Lab Med
|
2011
|
0.99
|
|
36
|
Wilms tumor gene product: sensitive and contextually specific marker of serous carcinomas of ovarian surface epithelial origin.
|
Appl Immunohistochem Mol Morphol
|
2004
|
0.99
|
|
37
|
Biomarker panel diagnosis of thyroid cancer: a critical review.
|
Expert Rev Anticancer Ther
|
2008
|
0.97
|
|
38
|
Utility of a comprehensive immunohistochemical panel in the differential diagnosis of spindle cell lesions of the urinary bladder.
|
Am J Surg Pathol
|
2009
|
0.96
|
|
39
|
BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations.
|
Am J Surg Pathol
|
2015
|
0.95
|
|
40
|
Ovarian atypical proliferative (borderline) mucinous tumors: gastrointestinal and seromucinous (endocervical-like) types are immunophenotypically distinctive.
|
Int J Gynecol Pathol
|
2006
|
0.94
|
|
41
|
Accuracy and precision in HER2/neu testing in breast cancer: are we there yet?
|
Hum Pathol
|
2004
|
0.94
|
|
42
|
IMP3 and GLUT-1 immunohistochemistry for distinguishing benign from malignant mesothelial proliferations.
|
Am J Surg Pathol
|
2013
|
0.93
|
|
43
|
Immunohistochemical markers of melanocytic tumors.
|
Int J Surg Pathol
|
2003
|
0.91
|
|
44
|
Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens.
|
Am J Surg Pathol
|
2016
|
0.87
|
|
45
|
Estrogen receptor alpha and progesterone receptor expression in ovarian adult granulosa cell tumors and Sertoli-Leydig cell tumors.
|
Int J Gynecol Pathol
|
2007
|
0.82
|
|
46
|
Relationship between clinical and pathologic features of ductal carcinoma in situ and patient age: an analysis of 657 patients.
|
Am J Surg Pathol
|
2009
|
0.82
|
|
47
|
PAX8 expression in uterine adenocarcinomas and mesonephric proliferations.
|
Int J Gynecol Pathol
|
2014
|
0.80
|
|
48
|
Mixed carcinoid and adenocarcinoma of the appendix: report of 4 cases with immunohistochemical studies and a review of the literature.
|
Appl Immunohistochem Mol Morphol
|
2004
|
0.80
|
|
49
|
Immunohistochemical characterization of squamous differentiation and morular metaplasia in uterine endometrioid adenocarcinoma.
|
Int J Gynecol Pathol
|
2013
|
0.79
|
|
50
|
Guidelines for Pathologic Diagnosis of Malignant Mesothelioma: 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.
|
Arch Pathol Lab Med
|
2017
|
0.79
|
|
51
|
HER2 in well differentiated breast cancer: is testing necessary?
|
Breast Cancer Res Treat
|
2008
|
0.78
|
|
52
|
BAP1 Immunohistochemistry and p16 FISH in the Diagnosis of Sarcomatous and Desmoplastic Mesotheliomas.
|
Am J Surg Pathol
|
2016
|
0.78
|
|
53
|
Testing for epidermal growth factor receptor in lung cancer: have we learned anything from HER-2 testing?
|
J Clin Oncol
|
2004
|
0.77
|
|
54
|
Testing for HER-2/neu in breast cancer: is fluorescence in situ hybridization superior in predicting outcome?
|
Adv Anat Pathol
|
2002
|
0.77
|
|
55
|
The knowns and the unknowns in HER2 testing in breast cancer.
|
Am J Clin Pathol
|
2011
|
0.76
|
|
56
|
GATA-3 expression in trophoblastic tissues: an immunohistochemical study of 445 cases, including diagnostic utility.
|
Am J Surg Pathol
|
2015
|
0.75
|
|
57
|
Fixation time does not affect expression of HER2/neu.
|
Am J Clin Pathol
|
2011
|
0.75
|
|
58
|
Concordance between human epidermal growth factor receptor 2 testing by reverse transcriptase polymerase chain reaction and fluorescent in situ hybridization.
|
J Clin Oncol
|
2012
|
0.75
|
|
59
|
Somatostatin receptor 2a is a more sensitive diagnostic marker of meningioma than epithelial membrane antigen.
|
Acta Neuropathol
|
2015
|
0.75
|
|
60
|
Personalized medicine-molecular targeted cancer therapy.
|
J Cell Mol Med
|
2009
|
0.75
|
|
61
|
PAX8 expression in uterine malignant mesodermal mixed tumor (carcinosarcoma).
|
Int J Gynecol Pathol
|
2014
|
0.75
|
|
62
|
Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder: a study of 45 cases.
|
Hum Pathol
|
2012
|
0.75
|
|
63
|
Tweaking and nudging toward improved-IHC quality.
|
Appl Immunohistochem Mol Morphol
|
2009
|
0.75
|
|
64
|
Controversies and guidelines in tissue-based HER-2/neu testing in breast cancer.
|
MLO Med Lab Obs
|
2002
|
0.75
|
|
65
|
Comparative Sensitivities and Specificities of Antibodies to Breast Markers GCDFP-15, Mammaglobin A, and Different Clones of Antibodies to GATA-3: A Study of 338 Tumors Using Whole Sections.
|
Appl Immunohistochem Mol Morphol
|
2016
|
0.75
|
|
66
|
Do we need two more mesothelial markers?
|
Hum Pathol
|
2005
|
0.75
|